Francisco Barros

Dr. Francisco Barros

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
JMJOSE MANUEL SOMOZA MARTÍN
JOSE MANUEL SOMOZA MARTÍN
FBFrancisco Barros
Francisco Barros
JRJosé Manuel Gándara Rey
José Manuel Gándara Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

1 June 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GNGuiomar Perez de Nanclares
Guiomar Perez de Nanclares
EFEduardo Fernández-Rebollo
Eduardo Fernández-Rebollo
ISIzortze Santin
Izortze Santin
BGBeatriz García-Cuartero
Beatriz García-Cuartero
SGSonia Gaztambide
Sonia Gaztambide
MBMurat Bastepe
Murat Bastepe
Context: Several endocrine disorders that share resistance to PTH are grouped under the term pseudohypoparathyroidism (PHP). PHP type I, associated with blunted PTH-induced nephrogenous cAMP formation and phosphate excretion, is subdivided according to the presence or absence of additional endocrine abnormalities, Albright’s hereditary osteodystrophy (AHO), and reduced Gsα activity caused by GNAS mutations. Objective: We sought to identify the molecular defect in four unrelated patients who were thought to have PHP-Ia because of PTH and TSH resistance and mild AHO features. Methods: Gsα activity and mutation analysis, and assessment of GNAS haplotype, methylation, and gene expression were performed for probands and family members. Results: Two patients showed modest decreases in erythrocyte Gsα activity. Instead of Gsα point mutations, however, all four patients showed methylation defects of the GNAS locus, a feature previously described only for PHP-Ib. Furthermore, one patient with an isolated loss of GNAS exon A/B methylation had the 3-kb STX16 deletion frequently identified in PHP-Ib patients. In all but one of the remaining patients, haplotype analysis excluded large deletions or uniparental disomy as the cause of the observed methylation changes. Conclusions: Our investigations indicate that an overlap may exist between molecular and clinical features of PHP-Ia and PHP-Ib. No current mechanisms can explain the AHO-like features of our patients, some of which may not be linked to GNAS. Therefore, patients with hormone resistance and AHO-like features in whom coding Gsα mutations have been excluded should be evaluated for epigenetic alterations within GNAS.

5 August 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
IFIsabel Ferreiros‐Vidal
Isabel Ferreiros‐Vidal
JGJuan J. Gomez‐Reino
Juan J. Gomez‐Reino
FBFrancisco Barros
Francisco Barros
ÁCÁngel Carracedo
Ángel Carracedo
PCPatricia Esmeralda Carreira
Patricia Esmeralda Carreira
AGAntonio Gonzalez
Antonio Gonzalez
Objective: The A allele of the PD1.3 single‐nucleotide polymorphism (SNP) on the programmed cell death gene PDCD1 was markedly more frequent in patients with systemic lupus erythematosus (SLE) than in unaffected controls in a recent study involving large sets of Swedish, European American, and Mexican families. This study sought to determine the role of PDCD1 in susceptibility to SLE in the Spanish population.Methods: Seven PDCD1 SNPs were studied in 518 SLE patients and 800 healthy control subjects who had been recruited in 5 distant towns spanning continental Spain. Patients and controls were of Spanish ancestry. The diagnosis of SLE was in accordance with the American College of Rheumatology updated classification criteria.Results: The A allele of the PD1.3 polymorphism was significantly less frequent in Spanish female patients with SLE than in Spanish female controls (9.0% versus 13.0%, odds ratio 0.67, 95% confidence interval 0.50–0.89). This difference was consistent across the 5 sets of samples grouped by town of recruitment. The other PDCD1 SNPs were not associated with SLE susceptibility. The haplotype structure of PDCD1 in the Spanish controls was different from that reported in other healthy control populations.Conclusion: Our results confirm the association of PDCD1 with susceptibility to SLE, but the findings show a lack of involvement of the PD1.3 SNP, which is contrary to the role of the PD1.3 A allele observed previously. These contradictory results probably reflect population differences in the haplotype structure of the PDCD1 locus. More research focusing on new polymorphisms and identifying associations in other populations will be needed to clarify the role of PDCD1 in SLE susceptibility.

1 May 2010 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
JMJOSE MANUEL SOMOZA MARTÍN
JOSE MANUEL SOMOZA MARTÍN
FBFrancisco Barros
Francisco Barros
JRJosé Manuel Gándara Rey
José Manuel Gándara Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

1 September 2010 in Cancer Letters
Verified
Journal Article
Closed access
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
JMJOSE MANUEL SOMOZA MARTÍN
JOSE MANUEL SOMOZA MARTÍN
FBFrancisco Barros
Francisco Barros
PDPilar Gayoso Diz
Pilar Gayoso Diz
JRJosé Manuel Gándara Rey
José Manuel Gándara Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

1 December 2011 in Cancer Letters
Verified
Journal Article
Closed access
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
JSJosé Manuel Suárez-Peñaranda
José Manuel Suárez-Peñaranda
GPGayoso-Diz Pilar
Gayoso-Diz Pilar
FBFrancisco Barros
Francisco Barros
JGJosé Manuel Gándara-Rey
José Manuel Gándara-Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia